NZ630843A - Treatment of brain cancer - Google Patents

Treatment of brain cancer

Info

Publication number
NZ630843A
NZ630843A NZ630843A NZ63084313A NZ630843A NZ 630843 A NZ630843 A NZ 630843A NZ 630843 A NZ630843 A NZ 630843A NZ 63084313 A NZ63084313 A NZ 63084313A NZ 630843 A NZ630843 A NZ 630843A
Authority
NZ
New Zealand
Prior art keywords
dihydrooxazol
triazolo
yloxy
pyridin
methylphenyl
Prior art date
Application number
NZ630843A
Other languages
English (en)
Inventor
Patrice A Lee
Shannon L Winski
Kevin Koch
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48048296&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ630843(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Priority to NZ724544A priority Critical patent/NZ724544A/en
Publication of NZ630843A publication Critical patent/NZ630843A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
NZ630843A 2012-03-23 2013-03-25 Treatment of brain cancer NZ630843A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ724544A NZ724544A (en) 2012-03-23 2013-03-25 Treatment of brain cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261615082P 2012-03-23 2012-03-23
PCT/US2013/033751 WO2013142875A1 (en) 2012-03-23 2013-03-25 Treatment of brain cancer

Publications (1)

Publication Number Publication Date
NZ630843A true NZ630843A (en) 2017-01-27

Family

ID=48048296

Family Applications (4)

Application Number Title Priority Date Filing Date
NZ630843A NZ630843A (en) 2012-03-23 2013-03-25 Treatment of brain cancer
NZ756264A NZ756264A (en) 2012-03-23 2013-03-25 Treatment of brain cancer
NZ74161513A NZ741615A (en) 2012-03-23 2013-03-25 Treatment of brain cancer
NZ724544A NZ724544A (en) 2012-03-23 2013-03-25 Treatment of brain cancer

Family Applications After (3)

Application Number Title Priority Date Filing Date
NZ756264A NZ756264A (en) 2012-03-23 2013-03-25 Treatment of brain cancer
NZ74161513A NZ741615A (en) 2012-03-23 2013-03-25 Treatment of brain cancer
NZ724544A NZ724544A (en) 2012-03-23 2013-03-25 Treatment of brain cancer

Country Status (30)

Country Link
US (3) US20150110780A1 (https=)
EP (4) EP4252855A3 (https=)
JP (6) JP2015514075A (https=)
KR (3) KR102490961B1 (https=)
CN (2) CN104203279B (https=)
AU (4) AU2013234921A1 (https=)
CA (1) CA2867723C (https=)
CL (1) CL2014002497A1 (https=)
CO (1) CO7071139A2 (https=)
CY (2) CY1120204T1 (https=)
DK (2) DK3400943T3 (https=)
ES (2) ES2673165T3 (https=)
HR (1) HRP20180659T1 (https=)
HU (2) HUE053156T2 (https=)
IL (3) IL234627B (https=)
LT (1) LT2827900T (https=)
MX (1) MX354024B (https=)
MY (2) MY202114A (https=)
NZ (4) NZ630843A (https=)
PH (2) PH12021550360A1 (https=)
PL (2) PL3400943T3 (https=)
PT (2) PT2827900T (https=)
RS (1) RS57140B1 (https=)
RU (2) RU2672575C2 (https=)
SG (1) SG11201405954YA (https=)
SI (2) SI2827900T1 (https=)
SM (1) SMT201800251T1 (https=)
TR (1) TR201808450T4 (https=)
UA (1) UA122044C2 (https=)
WO (1) WO2013142875A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2629116C2 (ru) 2011-10-14 2017-08-24 Эррэй Биофарма Инк. Полиморфы arry-380, селективного ингибитора erbb2, и фармацевтические составы, содержащие их
BR122020010643B1 (pt) 2011-10-14 2022-05-17 Array Biopharma Inc Dispersão sólida, composições farmacêuticas compreendendo a referida dispersão, usos das composições farmacêuticas e processo de preparação de uma dispersão sólida
WO2013142875A1 (en) 2012-03-23 2013-09-26 Array Biopharma Inc. Treatment of brain cancer
US11078272B2 (en) 2017-03-09 2021-08-03 The Board Of Trustees Of The Leland Stanford Junior University Treatment of pediatric brain tumors with targeting of CD47 pathway
CA3060407A1 (en) 2017-04-28 2018-11-01 Seattle Genetics, Inc. Treatment of her2 positive cancers
IL276398B2 (en) 2018-01-31 2026-03-01 Deciphera Pharmaceuticals Llc Combination therapy for mastocytosis
KR102708177B1 (ko) 2018-01-31 2024-09-23 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양의 치료를 위한 병용 요법
US11298422B2 (en) * 2018-04-09 2022-04-12 Novocure Gmbh Treating tumors with TTFields and an aurora kinase inhibitor
CN109942576B (zh) * 2019-03-07 2020-09-11 上海工程技术大学 Irbinitinib及中间体的制备方法
EP3938363A1 (en) 2019-03-11 2022-01-19 Teva Pharmaceuticals International GmbH Solid state forms of ripretinib
CN111825604A (zh) * 2019-04-16 2020-10-27 宁波药腾医药科技有限公司 一种图卡替尼及其中间产物的合成方法
LT4013412T (lt) 2019-08-12 2026-03-25 Deciphera Pharmaceuticals, Llc Ripretinibas, skirtas virškinamojo trakto stromos navikų gydymui
HRP20231699T1 (hr) 2019-12-30 2024-05-10 Deciphera Pharmaceuticals, Llc Formulacije inhibitora amorfne kinaze i postupci njihove primjene
CN115243681B (zh) 2019-12-30 2024-08-16 德西费拉制药有限责任公司 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH690163A5 (fr) * 1995-07-28 2000-05-31 Symphar Sa Dérivés gem-diphosphonates substitués utiles en tant qu'agents anti-cancers.
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
RU2255765C2 (ru) * 2000-01-21 2005-07-10 Чилдренз Хоспитал Лос-Анджелес Способ ингибирования роста опухолей головного мозга с помощью отобранных антагонистов интегринов
WO2001091794A2 (en) 2000-05-30 2001-12-06 Virginia Commonwealth University Vitamin d3 analogs as radiosensitizers for the treatment of cancer
WO2005016346A1 (en) 2003-08-14 2005-02-24 Array Biopharma Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
CN1989112A (zh) * 2004-06-03 2007-06-27 史密丝克莱恩比彻姆（科克）有限公司 癌症治疗方法
BRPI0511754A (pt) 2004-06-03 2008-01-02 Smithkline Beechman Cork Ltd uso de um composto ou sais ou solvatos do mesmo
ES2364901T3 (es) 2005-11-15 2011-09-16 Array Biopharma, Inc. Procesos e intermedios para la preparación de derivados de n4-fenil-quinazolin-4-amina.
JP5068270B2 (ja) 2006-01-31 2012-11-07 ノバルティス アーゲー 癌を処置するためのｉｌ−１７アンタゴニスト抗体
CA2700673A1 (en) * 2007-09-24 2009-04-02 Tragara Pharmaceuticals, Inc. Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors
NZ602675A (en) 2008-03-18 2014-03-28 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
RU2629116C2 (ru) 2011-10-14 2017-08-24 Эррэй Биофарма Инк. Полиморфы arry-380, селективного ингибитора erbb2, и фармацевтические составы, содержащие их
BR122020010643B1 (pt) 2011-10-14 2022-05-17 Array Biopharma Inc Dispersão sólida, composições farmacêuticas compreendendo a referida dispersão, usos das composições farmacêuticas e processo de preparação de uma dispersão sólida
WO2013142875A1 (en) 2012-03-23 2013-09-26 Array Biopharma Inc. Treatment of brain cancer

Also Published As

Publication number Publication date
KR20200115656A (ko) 2020-10-07
CA2867723A1 (en) 2013-09-26
AU2021261849A1 (en) 2021-12-02
IL269205A (en) 2019-11-28
PT3400943T (pt) 2021-02-02
JP2019081792A (ja) 2019-05-30
KR102490961B1 (ko) 2023-01-19
CN104203279A (zh) 2014-12-10
JP2021178820A (ja) 2021-11-18
KR20140139009A (ko) 2014-12-04
US20230190749A1 (en) 2023-06-22
HK1206276A1 (en) 2016-01-08
RU2014142700A (ru) 2016-05-20
EP4252855A3 (en) 2023-11-15
SMT201800251T1 (it) 2018-07-17
JP6898960B2 (ja) 2021-07-07
HUE037966T2 (hu) 2018-09-28
JP2022190126A (ja) 2022-12-22
HRP20180659T1 (hr) 2018-06-01
EP3400943B1 (en) 2020-12-02
SI2827900T1 (en) 2018-06-29
AU2019203618B2 (en) 2021-08-05
RU2018138976A3 (https=) 2022-04-08
CY1123837T1 (el) 2022-05-27
PL3400943T3 (pl) 2021-06-14
JP2024019526A (ja) 2024-02-09
PH12014502032A1 (en) 2014-11-24
ES2855142T3 (es) 2021-09-23
JP7404485B2 (ja) 2023-12-25
EP4252855A2 (en) 2023-10-04
AU2013234921A1 (en) 2014-10-02
CN104203279B (zh) 2018-10-30
DK2827900T3 (en) 2018-05-07
CA2867723C (en) 2022-11-08
NZ756264A (en) 2022-09-30
RS57140B1 (sr) 2018-07-31
CY1120204T1 (el) 2018-12-12
JP2015514075A (ja) 2015-05-18
AU2017272232C1 (en) 2019-08-15
TR201808450T4 (tr) 2018-07-23
EP2827900B1 (en) 2018-03-21
US20190255051A1 (en) 2019-08-22
NZ741615A (en) 2019-10-25
MY202114A (en) 2024-04-04
EP3842044A1 (en) 2021-06-30
ES2673165T3 (es) 2018-06-20
PH12021550360A1 (en) 2023-04-03
HUE053156T2 (hu) 2021-06-28
KR102160462B1 (ko) 2020-09-28
AU2017272232A1 (en) 2018-01-04
IL261659A (en) 2018-10-31
MY174883A (en) 2020-05-20
EP3400943A1 (en) 2018-11-14
SG11201405954YA (en) 2014-10-30
EP2827900A1 (en) 2015-01-28
DK3400943T3 (da) 2021-02-08
LT2827900T (lt) 2018-05-10
WO2013142875A1 (en) 2013-09-26
MX2014011437A (es) 2014-11-10
KR20210131426A (ko) 2021-11-02
PT2827900T (pt) 2018-06-14
AU2019203618A1 (en) 2019-06-13
US20150110780A1 (en) 2015-04-23
JP2017141302A (ja) 2017-08-17
SI3400943T1 (sl) 2021-03-31
IL269205B (en) 2020-06-30
IL234627B (en) 2018-10-31
MX354024B (es) 2018-02-08
PL2827900T3 (pl) 2018-08-31
US11504370B2 (en) 2022-11-22
CL2014002497A1 (es) 2014-11-14
CO7071139A2 (es) 2014-09-30
KR102317166B1 (ko) 2021-10-26
RU2672575C2 (ru) 2018-11-16
RU2018138976A (ru) 2018-12-06
NZ724544A (en) 2018-05-25
UA122044C2 (uk) 2020-09-10
AU2017272232B2 (en) 2019-02-28
CN109223791A (zh) 2019-01-18

Similar Documents

Publication Publication Date Title
NZ630843A (en) Treatment of brain cancer
CL2014000930A1 (es) Dispersion solida que comprende n4-(4-([1,2,4]triazolo-[1,5-a]piridina-7-iloxi)-3-metilfenil)-n6-(4,4-dimetil-4,5-dihidrooxazol-2-il)quinazolina-4,6-diamina y un polimero de dispersion; proceso de preparacion; composicion farmaceutica; uso en el tratamiento del cancer de mama, gastrico, colorectal, pancreatico, entre otros.
EA201490891A1 (ru) Пиридопиразины, обладающие противораковой активностью через ингибирование fgfr киназ
PH12015501965B1 (en) Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
CL2014001729A1 (es) Compuestos derivados de tieno (3,2-d) pirimidina, inhibidores de quinasas; composicion farmaceutica; y su uso en la prevencion o tratamiento de una enfermedad relacionada con quinasas como cancer.
EA201490194A1 (ru) Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака
GB201205669D0 (en) Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
SI2766040T1 (sl) Pertuzumab, Trastuzumab, Docetaxel in Carboplatin za zdravljenje zgodnjega raka dojke
EA201491584A1 (ru) Способы лечения немелкоклеточного рака легких c применением комбинированного лечения с ингибитором киназы tor
PH12014500809A1 (en) Polymorphs of arry-380, a slective herb2 inhibitor and pharmaceutical compositions containing them
PE20191655A1 (es) Combinaciones farmaceuticas
CL2014001282A1 (es) Uso de un inmunoconjugado de un anticuerpo dirigido contra el receptor del factor de crecimiento epidérmico (egfr) para el tratamiento del cáncer resistente al tratamiento dirigido contra egfr, donde el inmunoconjugado es un anticuerpo enlazado a un agente citotóxico.
PH12014502547A1 (en) Dosage regimen for a pi-3 kinase inhibitor
NZ598171A (en) Methods and compositions for treating thyroid-related medical conditions with reduced folates
PH12015502747A1 (en) Novel compounds for the treatment of cancer
WO2015082376A3 (en) Use of substituted 2,3-dihydroimidazo[1,2-c] quinazolines for the treatment of cancer
CA2909448C (en) Combination of a pi3 kinase inhibitor with paclitaxel for use in the treatment or prevention of a cancer of the head and neck
UA111383C2 (uk) Тверда дисперсія
MX2013002383A (es) Sales bromhidrato de una pirazolilaminoquinazolina.
HK1187527A1 (en) N-carboxyalkyl auristatins and the use thereof

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 25 MAR 2020 BY COMPUTER PACKAGES INC

Effective date: 20170531

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 MAR 2021 BY COMPUTER PACKAGES INC

Effective date: 20200303

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 MAR 2022 BY THOMSON REUTERS

Effective date: 20210206

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 MAR 2023 BY THOMSON REUTERS

Effective date: 20220302

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 MAR 2024 BY THOMSON REUTERS

Effective date: 20230201

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 MAR 2025 BY THOMSON REUTERS

Effective date: 20240201

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 MAR 2026 BY THOMSON REUTERS

Effective date: 20250203

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 MAR 2027 BY THOMSON REUTERS

Effective date: 20260202